PNPLA3 and metabolic dysfunction-associated steatotic liver disease: The German Diabetes Study registered as a clinical trial with 917 patients demonstrated that patients with severe insulin resistance diabetes are more likely to be carriers of the PNPLA3 gene mutation and suggested that carriers of this mutation have lipotoxic environments that could promote insulin resistance and NAFLD development [100].